We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





Non-Invasive COVID-19 Diagnostic System Collects Sample Droplets from Lungs and Returns Results in 10 Minutes

By LabMedica International staff writers
Posted on 22 Jul 2021
Print article
Image: Novel BlowFISH device that captures virus within Exhaled Breath Condensate (EBC) (Photo courtesy of Medivolve Inc.)
Image: Novel BlowFISH device that captures virus within Exhaled Breath Condensate (EBC) (Photo courtesy of Medivolve Inc.)
A non-invasive exhaled breath diagnostic technology offers the potential for a simple, inexpensive, non-invasive, massively deployable, rapid diagnostic system for detecting respiratory illness and airborne viral threats, including COVID-19, in approximately 10 minutes.

The non-invasive exhaled breath diagnostic technology, BlowFISH, developed by Marvel Diagnostics Inc. based at University of California (Los Angeles, CA, USA) and funded by Medivolve Inc. (Toronto, Canada) has successfully cleared the first milestone in a series of clinical tests targeting application of an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) to test for the COVID-19 virus. During the clinical trial, BlowFISH’s proprietary technology, designed to efficiently collect a substantial liquid sampling directly from deep within the lungs, successfully detected the COVID-19 virus in three test samples.

“This is an exciting and important milestone in advancing BlowFISH toward achieving EUA status in testing for COVID-19, and providing a non-invasive, cost-effective and scalable testing alternative to nasal swab solutions currently in market," said David Preiner, CEO, Medivolve. “Making testing more accessible to populations, such as children and the elderly, where it may be difficult to administer a nasopharyngeal swab test, will become important in our transition to resuming daily life in the 'new normal'.”

“BlowFISH’s detection of the COVID-19 virus brings us one significant step closer to changing the future of diagnostics for not only COVID-19, but for a wide range of respiratory illnesses,” said Dr. Pirouz Kavehpour, UCLA Professor and Marvel Diagnostics Co-Founder. “We are moving forward with urgency through proof-of-concept clinical trials, as these studies are a critical next step in making respiratory testing more comfortable, convenient and accessible for all...one breath at a time.”

Related Links:
Medivolve Inc.

New
Gold Supplier
SARS-CoV-2 S-IgG Antibody Assay
Lumipulse G SARS-CoV-2 S-IgG
New
Silver Supplier
Automated Nucleic Acid Extractor
NE48/96
New
Silver Supplier
Cartridge Incubator
WS-i60 Cartridge Incubator
New
Giardia, Cryptosporidium and E. Histolytica Antigen Test
TRI-COMBO PARASITE SCREEN

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.